![BioVision/Human CellExp™ LDL R, Fc Tag, Human recombinant/P1128/](images/biovison/p1128.jpg)
Alternate Name | LDLR, FH, FHC, LDLCQ2 |
---|---|
Gene Symbol | LDLR |
Gene ID | 3949 |
Accession # | P01130 |
Source | HEK 293 cells |
Appearance | Lyophilized |
Physical Form Description | Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Trehalose is added as protectant before lyophilization. |
Molecular Weight | 111.4 kDa |
Purity by SDS-PAGE | > 95% |
Endotoxin Level | < 1.0="" eu=""> |
Biological Activity | Immobilized Human PCSK9, His Tag at 5μg/mL (100 μL/well) can bind Human LDL R, Fc Tag with a linear range of 8-320 ng/mL. |
Reconstitution Instructions | Reconstitute in sterile deionized water to the desired protein concentration. |
Handling | Centrifuge the vial prior to opening. |
Storage Conditions | -20°C |
Shipping Conditions | Gel Pack |
USAGE | For Research Use Only! Not For Use in Humans. |
Description:
Low-Density Lipoprotein (LDL) Receptor is also known as LDLR, FH, FHC, LDLCQ2, and is a mosaic protein of ~840 amino acids (after removal of signal peptide) that mediates the endocytosis of cholesterol-rich LDL. It is a cell-surface receptor that recognizes the apoprotein B100 which is embedded in the phospholipid outer layer of LDL particles. The receptor also recognizes the apoE protein found in chylomicron remnants and VLDL remnants (IDL). It belongs to the Low density lipoprotein receptor gene family. LDL receptor complexes are present in clathrin-coated pits (or buds) on the cell surface, which when bound to LDL-cholesterol via adaptin, are pinched off to form clathrin-coated vesicles inside the cell. This allows LDL-cholesterol to be bound and internalized in a process known as endocytosis and prevents the LDL just diffusing around the membrane surface. This occurs in all nucleated cells (not erythrocytes), but mainly in the liver which removes ~70% of LDL from the circulation. Synthesis of receptors in the cell is regulated by the level of free intracellular cholesterol; if it is in excess for the needs of the cell then the transcription of the receptor gene will be inhibited. LDL receptors are translated by ribosomes on the endoplasmic reticulum and are modified by the Golgi apparatus before travelling in vesicles to the cell surface. LDL is directly involved in the development of atherosclerosis, due to accumulation of LDL-cholesterol in the blood. Atherosclerosis is the process responsible for the majority of cardiovascular diseases.ebiomall.com
![公司介绍](/themes/default/images/goods_detail/img_introduction.png)
![](/themes/default/images/goods_detail/company_introduction_bg.png)
![](/themes/default/images/goods_detail/bg_real.png)
![](/themes/default/images/goods_detail/bg_delivery.png)
![](/themes/default/images/goods_detail/bg_express.png)
![](/themes/default/images/goods_detail/bg_service.png)
>
>
>
>
>
>
>
>
>
>
>
>
如果是做科研,国内外很多知名的药企都是你学习借鉴的榜样。
生物制品细胞制备过程中不得使用青霉素或β-内酰胺(β-Lactam)类抗生素,明确表明不准使用青霉素。那么进行的重组蛋白类表达的微生物发酵,可以用青霉素吗?
2、2015版药典三部,各论中指出,”将检定合格的工作种子批菌种接种于适宜培养基(可含适量抗生素)中培养“,”发酵用培养基(采用适宜的不含抗生素的培养基)“。
这里说明种子培养基中可以使用抗生素,而且也没有限定究竟是哪种抗生素。
3、关于发酵中使用的抗生素,不知大家一般用哪家的,一些常用的,氨苄西林钠,硫酸卡那霉素,氯霉素等,都是用的什么级别,那个厂家的呢?我现在生工的,阿拉丁的,生兴生物的都用过。主要还是用的生工生物的,但是生工生物的抗生素都是进口分装的,不仅仅抗生素,国内很多进口分装的试剂,都无法提供相应的产品质量检测证书。而且因为是分装的,基本也就属于只有销售,所以,以后真的生产了,原材料来源的稳定性也无法保证。请问这个问题,大家是怎么解决的,一般用的哪家的呢。
最近留意了几个消息,发现生产线一家比一家大,结合最近国家在搞药品上市许可持有人制度试点,五年以后这行业竞争会有多激烈,产能会不会过剩的。
百迈博生产线6000升(3000*2)
东耀生产线10000升(2000*5)
三生制药生产线30000升(5000*6)
信达生物生产线>15000升
百泰生物生产线4000升
药明康德生产线2000升(不知现在规模有没有扩大)
还有很多低调的公司可能规模更大……
将来在国内,按照现有的产量结合所有生产线的总和生产出来的重组蛋白会不会以白菜价进入市场的,
大家好,想请教大家一个关于HPLC方法学的问题。
目前我们做的一个蛋白药,没有标准品,液相建立一个方法只想用于纯度鉴定,不去定量,这个方法所得到的图谱就一个主蛋白峰,面积归一化法相当于100%,现在就这个方法的方法学验证提出下面几点疑问:
1.因为我只做纯度鉴定,这个方法的方法学应该做系统适用性、专属性、检测限、耐用性和精密度这些,还是按照定量的全套加上定量限、线性、范围、准确度这些?
2.纯度鉴定中,我觉得应该对杂质进行定量,但是我们的这个方法只有一个主蛋白峰,几乎没有杂质峰,这样的话这个方法学我应该以什么为标准证明纯度呢?需将样品进行适当的氧化、酸、碱破坏吗?然后证明破坏后主峰能和产生的杂质分开?
3.对应生物蛋白药的杂质,应该属于无法获得的,如果通过强破坏,这个杂质也是不好鉴定的,是不是我只需要知道主峰能和强破坏的降解物分开,就可以说方法建立成功?还是生物药没有必要做这个强破坏,简单的走一下系统适用性、专属性、检测限、耐用性和精密度这样的流程就行?
说的有点乱,主要是自己对这个生物药的HPLC纯度鉴定的方法学,实在是疑惑重重,希望有经验的大侠能帮忙解答下。非常感谢!
事实上,现在多数药用级别白蛋白都是用血清生产的.
白蛋白的销售方向若是面向实验室,可采用重组质粒转到微生物发酵的方法生产,对土地面积的要求小,更集约,成本效率更高.
![](/themes/default/images/img_brandintro.png)
![品牌介绍](/data/brandlogo/1504043299937390967.jpg)
暂无品牌分类